Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Ambry Genetics Partners RainDance For Diagnostics, Genomics Services

Ambry Genetics, a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California and RainDance Technologies have jointly reported their partnership at the Annual CHI next generation Sequencing Conference in San Diego, CA, utilizing the RDT 1000 for sequence enrichment and resequencing validation.

Researchers can utilize the RDT 1000 and Ambry Genetics next generation services to either reduce study time, or to improve study quality by running more samples in the same time within the same experimental budget.

RainDance claimed that its technology platform delivers sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery or conduct clinical diagnostics.

RainDance said that the core RainStorm technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible and low-cost manner. RainDance’s commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis.

Chris McNary, chief commercial officer of RainDance Technologies, said: “We’re pleased to partner with Ambry Genetics to provide our microdroplet PCR-based solution in conjunction with Ambry’s genetic testing and next generation sequencing services. PCR is the gold standard for sequence enrichment and allows for high-resolution analysis of rare genetic variations, a focus area of Ambry Genetics’ customers.

“Ambry is currently offering RainDance’s sequence enrichment solution and may add two new applications, Methyl-Seq and Ultra-Deep Resequencing in the second half of 2010, further enhancing their customers’ ability to understand the origins and pathways of complex diseases.”

Ardy Arianpour, director of business development, said: “Ambry Genetics has dedicated its investments in technology for the benefit of the scientific and research community. We are motivated to provide our Diagnostic, Genomic and Research customers with the best solutions for their projects, and the addition of RainDance’s RDT 1000 adds a sequence-enrichment offering while providing an option for customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness and speed.”

Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Ambry has built a reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research.